Table 1.
Baseline characteristics of patients before treatment
| Characteristics | Before treatment |
| Sex, M/F | 42/4 |
| Age, yr, median (range) | 53.5 (36-70) |
| BCLC stage B/C 1 | 42/4 |
| Child–Pugh class A/B/C | 45/1/0 |
| ECOG performance status 0/12 | 42/4/0 |
| Laboratory values, median (range) | |
| WBC count, 109/L | 4.98 (2.23-10.09) |
| Platelet count, 109/L | 158 (49-371) |
| Hemoglobin, g/dL | 135 (76-159) |
| Serum AST, IU/L | 18.85 (16.20-101.60) |
| Serum ALT, IU/L | 28.7 (9.6-178.8) |
| Serum total bilirubin, mg/dL | 13.2 (5.0-41.4) |
| Serum albumin, g/dL | 38.45 (28.8-45.1) |
| INR | 1.10 (0.92-1.33) |
| Serum creatinine, mg/dL | 65.05 (40.30-106.20) |
| Serum AFP, ng/mL, baseline < 20 | 7.86 (1.28-24200.00) (n = 29) |
| Serum AFP, ng/mL, baseline > 20 | 170.80 (20.02-24200.00) (n = 17) |
| Tumor burden and distribution | |
| Unifocal/multifocal | 35/11 |
| Unilobar/bilobar | 44/2 |
| Lesion diameter (cm) | |
| Largest lesion diameter (mean, range) | 14.0 (9.47, 8.2-14.0) |
1
Barcelona Clinic Liver Cancer staging system.
2
Eastern Cooperative Oncology Group performance status. BCLC: Barcelona Clinic Liver Cancer; ECOG: Eastern Cooperative Oncology Group; WBC: White blood cell; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; INR: International Normalized Ratio; AFP: α-fetoprotein.